A comprehensive view of Moderna Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023

Moderna expands partnership with Swiss biopharma CDMO Lonza to increase production of COVID-19 vaccine drug substances; Lonza to add new manufacturing line at Geleen, Netherlands, plant with capacity to add up 300 million doses per year

Moderna granted FDA breakthrough therapy designation for its mRNA-1345 investigational RSV vaccine candidate in adults aged 60 years and older; in US, about 60,000-120,000 older adults are hospitalized with RSV every year

Moderna hiring about 2,000 new employees in 2023, with many filling roles in technical development, chemistry, manufacturing, controls as company has clinical wins with mRNA candidates for melanoma, RSV; many of the new jobs to be located in Massachusetts

Moderna, Inc. Files SEC Form 8-K, Current Report: (Jan. 9, 2023)

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count